Trends in Prescribing of Antipsychotic Medications for US Children

Ambulatory Pediatrics

Volumn 6, Issue 2, 2006, Pages 79-83

  Cooper, William O ^a   Arbogast, Patrick G ^b   Ding, Hua ^b   Hickson, Gerald B ^a   Fuchs, D Catherine ^b   Ray, Wayne A ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

antipsychotics; children; mental health; prescribing trends

Indexed keywords

ACETOPHENAZINE; CARFENAZINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE SUCCINATE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPERTINE; PERPHENAZINE; PIMOZIDE; PIPERACETAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADOLESCENT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CHILD HEALTH CARE; CONDUCT DISORDER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG INDICATION; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MOOD DISORDER; PHARMACEUTICAL CARE; PRESCRIPTION; SCHIZOPHRENIA; UNITED STATES; AGE DISTRIBUTION; AMBULATORY CARE; DRUG UTILIZATION; EPIDEMIOLOGY; INCIDENCE; PRESCHOOL CHILD; PROBABILITY; PSYCHOSIS; REGISTER; RISK ASSESSMENT; SEX RATIO; STATISTICS;

ADOLESCENT; AGE DISTRIBUTION; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; MALE; PRESCRIPTIONS, DRUG; PROBABILITY; PSYCHOTIC DISORDERS; REGISTRIES; RISK ASSESSMENT; SEX DISTRIBUTION; UNITED STATES;

EID: 33645737575     PISSN: 15301567     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ambp.2005.11.002     Document Type: Article

References (31)

1. Cooper W.O., Hickson G.B., Fuchs C., et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158 (2004) 753-759
2. Zito J.M., Safer D.J., Dosreis S., et al. Psychotropic practice patterns for youth. a 10-year perspective. Arch Pediatr Adolesc Med 157 (2003) 17-25
3. Patel N.C., Crismon M.L., Hoagwood K., et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 44 (2005) 548-556
4. Campbell M., Rapoport J.L., and Simpson G.M. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38 (1999) 537-545
5. Cortese L., Pourcher-Bouchard E., and Williams R. Assessment and management of antipsychotic-induced adverse events. Can J Psychiatry 43 suppl 1 (1998) 15S-20S
6. Ratzoni G., Gothelf D., Brand-Gothelf A., et al. Weight gain associated with olanzapine and risperidone in adolescent patients. a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41 (2002) 337-343
7. Buse J.B., Cavazzoni P., Hornbuckle K., et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56 (2003) 164-170
8. Gianfrancesco F., Grogg A., Mahmoud R., et al. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25 (2003) 1150-1171
9. Wieck A., and Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 182 (2003) 199-204
10. Wudarsky M., Nicolson R., Hamburger S.D., et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9 (1999) 239-245
11. Jordan M.P. Ziprasidone-associated galactorrhea in a female teenager. J Am Acad Child Adolesc Psychiatry 42 (2003) 4-5
12. Safer D.J. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24 (2004) 429-436
13. Patel N.C., Kistler J.S., James E.B., and Crismon M.L. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 24 (2004) 824-830
14. Blair J., Scahill L., State M., and Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone. a prospective study. J Am Acad Child Adolesc Psychiatry 44 (2005) 73-79
15. Findling R.L., McNamara N.K., Branicky L.A., et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39 (2000) 509-516
16. Gerardin P., Cohen D., Mazet P., and Flament M.F. Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol 12 (2002) 361-370
17. Cheng-Shannon J., McGough J.J., Pataki C., and McCracken J.T. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14 (2004) 372-394
18. Vitiello B. Psychopharmacology for young children. clinical needs and research opportunities. Pediatrics 108 (2001) 983-989
19. Safer D.J., Zito J.M., and Dosreis S. Concomitant psychotropic medication for youths. Am J Psychiatry 160 (2003) 438-449
20. National Center for Health Statistics.National Health Care Survey.Available athttp://www.cdc.gov/nchs/nhcs.htmAccessed January 17, 2005
21. US Bureau of the Census. US Census Bureau Population Estimates. http://www.census.gov/popest/estimates.php10/5/04.
22. Cochran W. Sampling Techniques. 3rd ed. (1977), John Wiley & Sons, New York, NY
23. Casella G., and Berger R.L. Statistical Inference. 2nd ed (2002), Duxbury Press, Duxbury, Calif
24. Kendell R.E., Malcolm D.E., and Adams W. The problem of detecting changes in the incidence of schizophrenia. Br J Psychiatry 162 (1993) 212-218
25. Morensen P. Schizophrenia and society. an epidemiological perspective. In: Mallarkey G. (Ed). Managing Schizophrenia (2000), Adis International Publications, Kwai Chung, Hong Kong 1-8
26. Zito J.M., Safer D.J., Dosreis S., et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283 (2000) 1025-1030
27. Snyder R., Turgay A., Aman M., et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41 (2002) 1026-1036
28. Van B.M., and De T.C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning. a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11 (2001) 5-13
29. McCracken J.T., McGough J., Shah B., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002) 314-321
30. Malone R.P., Maislin G., Choudhury M.S., et al. Risperidone treatment in children and adolescents with autism. short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41 (2002) 140-147
31. Masi G., Cosenza A., Mucci M., and Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40 (2001) 1206-1214